scispace - formally typeset
Search or ask a question

Showing papers by "Regulus Therapeutics published in 2021"

Journal Article•DOI•
miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.

[...]

Vera Usuelli1, Moufida Ben Nasr2, Moufida Ben Nasr1, Francesca D'Addio1, Kaifeng Liu2, Andrea Vergani2, Basset El Essawy3, Basset El Essawy4, Jun Yang5, Emma Assi1, Mayuko Uehara4, Chiara Rossi6, Anna Solini6, Annalisa Capobianco7, Elena Rigamonti7, Luciano Potena8, Massimo Venturini, M. Sabatino8, Lorena Bottarelli9, Enrico Ammirati, Maria Frigerio, Eduardo Castillo-Leon2, Anna Maestroni1, Cinzia Azzoni9, Cristian Loretelli1, Andy Joe Seelam1, Albert K. Tai10, Ida Pastore, Gabriella Becchi9, Domenico Corradi9, Gary A. Visner2, Gian Vincenzo Zuccotti1, Gian Vincenzo Zuccotti2, B. Nelson Chau11, Reza Abdi4, Marcus G. Pezzolesi12, Paolo Fiorina2, Paolo Fiorina1 •
University of Milan1, Boston Children's Hospital2, Al-Azhar University3, Brigham and Women's Hospital4, Huazhong University of Science and Technology5, University of Pisa6, Vita-Salute San Raffaele University7, University of Bologna8, University of Parma9, Tufts University10, Regulus Therapeutics11, University of Utah12
25 Mar 2021-American Journal of Transplantation
TL;DR: In this paper, the miRNA network involved in chronic allograft vasculopathy (CAV) remains an impediment to long-term graft survival, despite much progress in improving graft outcome during cardiac transplantation.

9 citations

Patent•
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

[...]

Charles R. Allerson1, S. Neben1, Wright Timothy•
Regulus Therapeutics1
23 Feb 2021
TL;DR: In this article, compositions and methods for the inhibition of miR-122 activity are described and administered to subjects infected with hepatitis C virus, as a treatment for hepatitisC virus and related conditions.
Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.